MACOP-B Chemotherapy for the treatment of high grade and intermediate grade Non Hodgkin's lymphoma

[1]  R A Olshen,et al.  Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Larson,et al.  Long-term survival of patients with intermediate and high grade lymphoma treated with COMLA/ABP. , 1990, Leukemia.

[3]  M. Engelhard,et al.  German-austrian multicenter trial for aggressive non-Hodgkin lymphomas: COP-BLAM/IMVP-16 chemotherapy with randomized adjuvant radiotherapy , 1988, Blut.

[4]  Goldie Jh,et al.  Impact of dose-intense chemotherapy on the development of permanent drug resistance. , 1987 .

[5]  E J Freireich,et al.  Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. , 1987, Science.

[6]  W. Velasquez,et al.  Results of MIME salvage regimen for recurrent or refractory lymphoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Jaffe Es.  Relationship of classification to biologic behavior of non-Hodgkin's lymphomas. , 1986 .

[8]  D. Weisenburger,et al.  Chemotherapy for diffuse large-cell lymphoma--rapidly responding patients have more durable remissions. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Connors,et al.  MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. , 1985, Annals of internal medicine.

[10]  R. Fisher,et al.  Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. , 1983, Annals of internal medicine.

[11]  G. Pinkus,et al.  Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Armitage,et al.  Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP) , 1982, Cancer.

[13]  F. Cabanillas,et al.  IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. , 1982, Blood.

[14]  M. Pasmantier,et al.  Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen. , 1982, Annals of internal medicine.

[15]  R. Fisher,et al.  Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. , 1981, Blood.

[16]  L. Norton,et al.  Nodular histiocytic lymphoma: an aggressive nodular lymphoma with potential for prolonged disease-free survival. , 1980, Blood.

[17]  V. Devita,et al.  Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. , 1976, Annals of internal medicine.

[18]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.

[19]  C. Spurr,et al.  Management of patients with malignant lymphoma: a comparative study with cyclophosphamide and vinca alkaloids. , 1968, Cancer research.

[20]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[21]  Robert N. Hughes,et al.  Cancer: Principles and Practice of Oncology , 2005 .

[22]  F. Herrmann,et al.  Minimal peripheral blood cells carrying clonal markers of B cell disorders: evidence for monoclonality of circulating lymphocytes in patients with multiple myeloma. , 1989, International journal of cell cloning.

[23]  J. Goldie,et al.  Impact of dose-intense chemotherapy on the development of permanent drug resistance. , 1987, Seminars in oncology.

[24]  E. Jaffe.  Relationship of classification to biologic behavior of non-Hodgkin's lymphomas. , 1986, Seminars in oncology.

[25]  D. Rosenthal,et al.  Methotrexate as a single agent and in combination chemotherapy for the treatment of non-Hodgkin's lymphoma of unfavorable histology. , 1981, Cancer treatment reports.